Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001312 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT01001312 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 22 participants.
The verdict
NCT01001312, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Heart failure is a common cardiac condition affecting nearly 6 million Americans. Silent blood volume overload is common in patients with heart failure and is associated with increased risk of death. This study is designed to determine if adjustment of therapy based on direct measurement of blood volume will reduce risk of hospitalization and death when compared with therapy based on clinical assessment of blood volume in patients with chronic heart failure.
Interventions
- OTHER Daxor Blood Volume Analysis
- OTHER Clinical volume status assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001312
The ClinicalTrials.gov registry entry for NCT01001312 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daxor Blood Volume Analysis is the first listed.
NCT01001312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001312 about?
NCT01001312 is a clinical study titled "Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure". Heart failure is a common cardiac condition affecting nearly 6 million Americans. Silent blood volume overload is common in patients with heart failure and is associated with increased risk of death. This study is designed to determine if adjustment of therapy based on direct measurement of blood vo...
What is the current status of trial NCT01001312?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2010-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01001312?
The interventions under investigation include: Daxor Blood Volume Analysis (OTHER), Clinical volume status assessment (OTHER).
Who is sponsoring clinical trial NCT01001312?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.